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ABSTRACT
Introduction: Patients who are discharged
following surgery on an oral opioid, and who
have taken the drug for 2 or more weeks
often experience withdrawal symptoms when
they try to discontinue the drug.
Case Report: Three weeks after discharge, a
44-year-old female patient decided to reduce
her oxycodone (OxyContin) dosage from
20 mg three times a day to 20 mg two times a
day. She experienced severe withdrawal
symptoms.
Method: To assist her in withdrawing from the
remainder of the drug, a protocol using
ondansetron was developed.
Results: After 10 days, the patient was opioid
and withdrawal-symptom free.
Conclusion: Use of ondansetron along with
tapering of the opioid was safe and effective in
preventing further withdrawal symptoms. This
case should stimulate research with a larger,
more diverse population including those with
both short-term and chronic opioid
dependence.
Keywords: Ondansetron; Opioid
withdrawal syndrome; Oxycodone; OxyContin
INTRODUCTION
Patients who have been prescribed an oral
opioid postoperatively and who take the drug
for 2 or more weeks usually report experiencing
withdrawal symptoms when the drug is
discontinued. This report describes the case of
an individual who was assisted in relieving her
physical dependence on oxycodone. It provides
an insight into the reason for her surgery,
the surgery itself, and her postoperative
course. It also reviews medications used, and
describes the protocol followed to produce
successful results.
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The patient, a female, was 14 years old when she
was diagnosed with scoliosis. She showed no
cosmetic effect, nor was there any pressure on her
internal organs related to the scoliosis. At age 44,
a rib on her left side became noticeably more
prominent and measurements showed that she
had lost close to two inches in height. She was in
good health and had a body mass index below 25.
Her only pain medication was an occasional
extra-strength acetaminophen. An assessment
by an orthopedic surgeon recommended by the
Scoliosis Research Society revealed that she had
also developed some neuropathy in her left lower
limb. A magnetic resonance imaging scan
verified thoracic dextroscoliosis and lumbar
levoscoliosis with degenerative changes in both
areas. Surgery was deemed medically necessary.
Her first surgery was accomplished through a
lower abdominal incision. Lumbar vertebra 5
(L5) was replaced by a titanium prosthesis, and
a donor bone graft was used to replace the disc.
The next day, surgery was performed anteriorly
from a left-side incision. A rib was removed, a
chest tube was inserted, and discs between T10,
T11, T12, and the remaining lumbar vertebrae
were temporarily replaced. After surgery, the
patient complained of quite a bit of referred
pain in her shoulder. She rested on days 3 and 4,
but was back in surgery for several hours on day
5. A posterior incision allowed the surgeon to
remove the discs from T3 to T9, rotate the
spinal column from 85 to 27, fixate it with
rods, screws, and wires, and insert donor bone
grafts between all the vertebra. Because the
vertebra were scraped to allow fusion with the
grafts, the patient required replacement of 14 U
of blood.
Postoperatively, the patient had intravenous
(i.v.) patient-controlled analgesia (PCA) with
morphine. Epidural analgesia was attempted
but did not provide any pain relief, so she was
maintained on the PCA through day 7. She was
then started on 20 mg of controlled-release
oxycodone (OxyContin; Purdue Pharma L.P.,
Stamford, CT, USA) to be taken orally (p.o.)
twice a day, with 5 mg of fast-release oxycodone
p.o. as needed for breakthrough pain. On day 9
her controlled-release oxycodone dose was
increased to 20 mg at 7:00 a.m., 3:00 p.m., and
11:00 p.m. Fast-release oxycodone 5 mg was
continued for breakthrough pain. She was
discharged from hospital that afternoon.
A bivalve orthosis (clamshell brace) and two
SpinalPak II Fusion Stimulators (EBI, LLC dba
Biomet Spine & Bone Healing Technologies,
Parsippany, NJ, USA) were prescribed to stabilize
the patient’s spine and to stimulate bone
growth. The following days were difficult for
her. They entailed making her position
comfortable, adjusting the clamshell, replacing
SpinalPak batteries, and relieving constipation
associated with the surgery and the opioids.
During the first week at home the patient took
approximately three oxycodone 5 mg tablets for
breakthrough pain, but by the following week
she was able to gradually discontinue it. She
became more active and was able to climb the
stairs to the second floor of the house in spite of
some left leg and foot neuropathy. She was
anxious to be able to drive her car, but thought
that she should not do so while she was still
taking the controlled-release oxycodone.
Twenty-five days after receiving her first
opioid and almost 3 weeks after discharge
from the hospital, the patient discontinued
the middle dose of oxycodone, contrary to
usual pain management protocols, which
recommend partial decreases at each dosage
time over many days. She decided to take 20 mg
of oxycodone at 8 a.m. and 20 mg at 8 p.m. By
5 p.m. that same day, she became anxious and
extremely depressed. She showed the following
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signs of withdrawal: crying, cold flashes,
piloerection, muscle twitches, tremors, hot
flashes, and perspiration. She described
symptoms of: abdominal cramps, feeling
nauseous and ready to vomit, shaking, and eye
twitching. These signs and symptoms lasted
over 48 h. She was afraid to reduce the
remaining doses of oxycodone and asked for
assistance.
METHODS
A review of the literature was conducted
through PubMed and yielded many articles
dealing with withdrawal from opiates.
Keywords used were ‘‘oxycontin,’’ ‘‘opioid
withdrawal,’’ ‘‘taper,’’ and after seeing a referral
in one article, ‘‘ondansetron.’’ A 1986 article
from the Johns Hopkins University Hospital [1]
described a pilot study of three adult post-addict
males who were given different doses of
morphine or placebo on 12 mornings followed
by 10 mg of naloxone in the afternoons. The
study showed that naloxone could precipitate
withdrawal signs and symptoms after acute
morphine administration similar to those
observed after chronic opioid use [1]. That
same year, a scientist from the UK reviewed
several studies and called attention to the fact
that cerebral membranes of both the rat and
humans contained sites that were characteristic
of 5-hydroxytryptamine3 (5-HT3) receptors. He
posited that 5-HT3 antagonists might have the
ability to block feelings of reward induced by
drug-craving addicts [2].
A Canadian study concluded that 5-HT3
antagonists (ondansetron, and MDL 72222)
might reduce some, but not all, signs and
symptoms of withdrawal behavior induced by
naloxone [3]. Other researchers varied in their
conclusions regarding the effectiveness of
ondansetron. One study found that it did not
reduce the cravings of opiate addicted rodents
[4], while another suggested that it could be
useful in lowering the rate of relapse [5]. Data
reported by a group from Italy confirmed that
naloxone precipitated withdrawal signs in
morphine-dependent rats, and, that ondansetron
prevented several of those signs [6].
In 2009, a research group from Stanford
University [7] assessed opioid withdrawal
behavior in 18 different strains of mice and in
eight human volunteers. The mice were treated
with subcutaneous (s.c.) morphine in increasing
doses over 4 days, assessed 18 h after the last
dose, and then given naloxone s.c. which
precipitated varied degrees of withdrawal
behavior depending upon the strain of the
mice used. The researchers used ondansetron,
to determine its effect on the morphine-
dependent mice. The ondansetron-treated
mice showed significantly decreased naloxone-
induced withdrawal behavior [7].
Eight human volunteers, all males, were
then recruited, and served as their own
controls. Baseline data were obtained by using
objective and subjective rating scales [8]. Four
volunteers received a 0.9% saline placebo
administered intravenously (i.v.) followed by
morphine 10 mg/70 kg (i.v.). The remaining
four volunteers were pretreated with 8 mg of
ondansetron (i.v.), and then received morphine
10 mg/70 kg (i.v.). Two hours after the first set
of drugs were administered, all participants
received 10 mg/70 kg of naloxone (i.v.) to
induce withdrawal symptoms. Seven days later
the volunteers were administered the same
drugs. The four men who had received
placebos in the first experiment received both
ondansetron and morphine while the
remaining four received the placebo and the
morphine. Both objective and subjective signs
of withdrawal were assessed and compared to
the baseline survey [7].
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Evaluation of the effects on all of the human
subjects showed that seven of the eight
volunteers developed 12 of 13 objective signs
of withdrawal. In all seven men, ondansetron
significantly reduced all 12 of those signs
(P = 0.0313). The 16 subjective symptoms,
however, were not shown to be significantly
lower with the use of ondansetron [7].
Drugs Used
The principle central nervous system effects of
opioids are analgesia, euphoria, sedation,
respiratory depression, cough suppression,
pupil constriction, and temperature changes.
Peripheral effects are sometimes seen on the
cardiovascular system in patients with
hypotension, in the gastrointestinal tract
(causing constipation), on the biliary tract, on
the functioning of the renal system, on the
neuroendocrine system, and in the skin
(causing pruritus and sweating). Effects are
also seen in the immune system.
People show physical dependence on opioids
when they are abruptly stopped. The number
and intensity of the signs and symptoms of
withdrawal are dependent upon the degree of
physical dependence that has developed.
Withdrawal signs usually start within 6–10 h
after the last dose [9]. Physical dependence
should not be confused with tolerance or
addiction. Tolerance, a gradual loss of
effectiveness, occurs during treatment when
large doses of opioid are given close together
[10]. Addiction is a relapsing compulsion to
obtain and use the drug even after successful
withdrawal and in spite of negative effects [9].
Ondansetron is a 5-HT3 antagonist that
blocks the action of serotonin. Serotonin is
both a powerful stimulant of pain and a strong
activator of chemosensitive endings [11].
Serotonin is accepted by 5-HT3 receptors
located in the chemoreceptor trigger zone of
the brain (area postrema), the vomiting center
in the medulla, and in the gastrointestinal tract.
It participates in the vomiting reflex, especially
in vomiting caused by chemical triggers [11].
Ondansetron is tolerated well and has an
excellent safety record. It has proved to be
therapeutic in preventing nausea and vomiting
related to surgery, chemotherapy, and whole
body or abdominal radiation therapy [12].
Ondansetron has been used in the treatment
of irritable bowel syndrome, and a Cochrane
Collaboration review described its use in
relieving acute gastroenteritis in children and
adolescents [13].
As for a safe dose in adults and children over
12 years of age, oral ondansetron is given as an
8 mg tablet, 30 min before and again 8 h after
an initial dose of chemotherapy or radiation
therapy. Then, 8 mg is given every 8–12 h for
1–2 days [14].
Intervention
The patient was assisted in becoming
oxycodone free, by tapering the doses of
oxycodone and by using ondansetron to make
the process more tolerable. Ondansetron had
reduced artificially induced withdrawal
symptoms for eight male volunteers [7], but
the question remained as to whether
ondansetron could help alleviate withdrawal
in a 44-year-old premenopausal woman who
had been on oxycodone for 5 weeks.
The patient obtained prescriptions for
oxycodone 10 mg and for oral ondansetron
8 mg. Ondansetron 8 mg was given at 8 a.m.
and 8 p.m. every day during the treatment
period. It began 48 h before the first dose
reduction in oxycodone and continued until
48 h after the last dose of oxycodone. The
evening dose of oxycodone was the first to be
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reduced to 10 mg. The planned protocol can be
seen in Table 1.
Institutional Review Board approval from the
University of Tennessee at Chattanooga and
written permission from the subject were
obtained. Verbal agreement was received from
the subject’s surgeon to allow dissemination of
information related to her surgery and
postoperative recovery.
RESULTS
During the 10 days of the weaning process, the
patient neither exhibited nor voiced any
symptoms of withdrawal from the opioid. In
fact, she expressed fear of becoming dependent
on the ondansetron because of the feeling of
well-being it gave her. She was reassured that
the ondansetron acted on different receptors in
the body than did the opioids, and that her
prior withdrawal symptoms had been normal
for what she had been through, and not
symptoms of addiction. This reassurance
stemmed from knowing that antidepressants,
which (like ondansetron) block serotonin
uptake, have not been shown to cause
addiction even after prolonged use [9].
At the conclusion of the protocol, the
patient disposed of the remaining oxycodone
according to the Food and Drug Administration
(FDA) guidelines. She was featured as a model
patient after a month of visits to a physical
therapy group. She continues to walk daily on
her treadmill and enjoys advanced hula-hoop
exercises on the WiiTM (Nintendo, Redmond,
WA, USA). Some may argue that the same effect
could have been achieved by simply tapering
the dose of opioids at a slower rate and over a
longer period of time. For instance, the patient
could have been advised to remove only 10 mg
of the middle dose of oxycodone, wait 4 days
and remove 10 mg of the evening dose, then
wait the same number of days and remove
10 mg of the morning dose. Since oxycodone
does not come in smaller doses than 10 mg, and
since controlled release could not be effectively
achieved by cutting the tablet in half (5 mg),
the patient may have had to endure some
withdrawal symptoms as the remaining doses
were discontinued over a 30-day period.
CONCLUSION
Reducing dependence on oxycodone is a big
hurdle for many people who have had
orthopedic or other major surgery. Statistics
are already showing increased percentages of
knee, hip, shoulder, and back surgery in people
born between 1946 and 1964 (‘‘baby boomers’’),
Table 1 A 10-day protocol for administering ondansetron









Day 1 8 a.m. X X
Day 1 8 p.m. X X
Day 2 8 a.m. X X
Day 2 8 p.m. X X
Day 3 8 a.m. X X
Day 3 8 p.m. X X
Day 4 8 a.m. X X
Day 4 8 p.m. X X
Day 5 8 a.m. X X
Day 5 8 p.m. X X
Day 6 8 a.m. X X
Day 6 8 p.m. X X
Day 7 8 a.m. X X
Day 7 8 p.m. X
Day 8 8 a.m. X X
Day 8 8 p.m. X
Day 9 8 a.m. X
Day 9 8 p.m. X
Day 10 8 a.m. X
Day 10 8 p.m. X
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an age group that has engaged in more active
sports than any previous generation. As these
people grow older, it can be postulated that
the incidence of oxycodone dependence will
increase. Military personnel are also seeing an
increase in opiate dependence [15]. To alleviate or
prevent the signs and symptoms of opioid
withdrawal and to combat the possibility of
some of these people becoming addicts, it would
be wise to conduct randomized controlled trials
on both males and females, young and old, with
both acute and chronic opioid dependence (not
associated with a terminal condition), to
determine the effects of ondansetron given prior
to beginning tapering off of the opioid.
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